The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
ALS patients experience neuroinflammation and rapid neurodegeneration
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
It is a novel oral NLRP3 inflammasome inhibitor
Subscribe To Our Newsletter & Stay Updated
